Hangzhou Tigermed Consulting (300347) - Total Assets

Latest as of March 2026: CN¥28.80 Billion CNY ≈ $4.21 Billion USD

Based on the latest financial reports, Hangzhou Tigermed Consulting (300347) holds total assets worth CN¥28.80 Billion CNY (≈ $4.21 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Hangzhou Tigermed Consulting cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Hangzhou Tigermed Consulting - Total Assets Trend (2009–2025)

This chart illustrates how Hangzhou Tigermed Consulting's total assets have evolved over time, based on quarterly financial data. See 300347 total equity for net asset value and shareholders' equity analysis.

Hangzhou Tigermed Consulting - Asset Composition Analysis

Current Asset Composition (December 2025)

Hangzhou Tigermed Consulting's total assets of CN¥28.80 Billion consist of 21.8% current assets and 78.2% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 6.3%
Accounts Receivable CN¥1.41 Billion 5.0%
Inventory CN¥41.50 Million 0.2%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥276.31 Million 1.0%
Goodwill CN¥3.52 Billion 12.4%

Asset Composition Trend (2009–2025)

This chart illustrates how Hangzhou Tigermed Consulting's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Hangzhou Tigermed Consulting worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Hangzhou Tigermed Consulting's current assets represent 21.8% of total assets in 2025, a decrease from 55.8% in 2009.
  • Cash Position: Cash and equivalents constituted 6.3% of total assets in 2025, down from 25.9% in 2009.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, a decrease from 17.0% in 2009.
  • Asset Diversification: The largest asset category is goodwill at 12.4% of total assets.

Hangzhou Tigermed Consulting Competitors by Total Assets

Key competitors of Hangzhou Tigermed Consulting based on total assets are shown below.

Company Country Total Assets
ICON Public Limited Company
F:IJF
Germany €16.51 Billion
Fleury S.A.
SA:FLRY3
Brazil R$13.33 Billion
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
China CN¥9.20 Billion
Diagnósticos da América S.A
SA:DASA3
Brazil R$21.10 Billion
Cowealth Medical China Co.Ltd.
SHG:603122
China CN¥1.41 Billion
Monash Ivf Group Ltd
AU:MVF
Australia AU$510.21 Million
Cytogen Inc
KQ:217330
Korea ₩62.24 Billion
Sonic Healthcare Ltd
AU:SHL
Australia AU$17.03 Billion

Hangzhou Tigermed Consulting - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.30 1.62 7.90
Quick Ratio 2.28 1.61 7.89
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥3.75 Billion CN¥2.26 Billion CN¥10.01 Billion

Hangzhou Tigermed Consulting - Advanced Valuation Insights

This section examines the relationship between Hangzhou Tigermed Consulting's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.27
Latest Market Cap to Assets Ratio 0.19
Asset Growth Rate (YoY) -1.1%
Total Assets CN¥28.36 Billion
Market Capitalization $5.36 Billion USD

Valuation Analysis

Below Book Valuation: The market values Hangzhou Tigermed Consulting's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Hangzhou Tigermed Consulting's assets decreased by 1.1% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Hangzhou Tigermed Consulting (2009–2025)

The table below shows the annual total assets of Hangzhou Tigermed Consulting from 2009 to 2025.

Year Total Assets Change
2025-12-31 CN¥28.36 Billion
≈ $4.15 Billion
-1.09%
2024-12-31 CN¥28.67 Billion
≈ $4.20 Billion
-3.40%
2023-12-31 CN¥29.68 Billion
≈ $4.34 Billion
+8.14%
2022-12-31 CN¥27.45 Billion
≈ $4.02 Billion
+15.61%
2021-12-31 CN¥23.74 Billion
≈ $3.47 Billion
+21.71%
2020-12-31 CN¥19.51 Billion
≈ $2.85 Billion
+157.74%
2019-12-31 CN¥7.57 Billion
≈ $1.11 Billion
+61.78%
2018-12-31 CN¥4.68 Billion
≈ $684.54 Million
+30.55%
2017-12-31 CN¥3.58 Billion
≈ $524.33 Million
+50.03%
2016-12-31 CN¥2.39 Billion
≈ $349.49 Million
+48.34%
2015-12-31 CN¥1.61 Billion
≈ $235.60 Million
+18.59%
2014-12-31 CN¥1.36 Billion
≈ $198.66 Million
+68.02%
2013-12-31 CN¥808.01 Million
≈ $118.24 Million
+10.26%
2012-12-31 CN¥732.84 Million
≈ $107.24 Million
+292.40%
2011-12-31 CN¥186.76 Million
≈ $27.33 Million
+55.75%
2010-12-31 CN¥119.91 Million
≈ $17.55 Million
+77.94%
2009-12-31 CN¥67.39 Million
≈ $9.86 Million
--

About Hangzhou Tigermed Consulting

SHE:300347 China Diagnostics & Research
Market Cap
$5.36 Billion
CN¥36.62 Billion CNY
Market Cap Rank
#3388 Global
#452 in China
Share Price
CN¥49.63
Change (1 day)
-0.72%
52-Week Range
CN¥36.17 - CN¥69.86
All Time High
CN¥43083.62
About

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more